Poly(Lactic-Co-Glycolic Acid) Based Drug Delivery Devices For Tissue Engineering And Regenerative Medicine

Kerımoğlu, Oya; Alarçin, Emine

doi:10.5222/ankem.2012.086

Cited by 32 publications

(17 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,21 A previous report has suggested that PLGA is associated with an increased risk of arterial thrombosis in a rat model of carotid angioplasty, 17 however this result is to be interpreted cautiously given its small sample size (n=4). In addition, the high rate of thrombosis seen with the rapamycin-loaded PLGA-construct used might have been more strongly related to inherent cytotoxicity associated with the drug rather than to the biomaterial.…”

Section: Discussionmentioning

confidence: 99%

“…14–17 Amongst the available biomaterials, PLGA is particularly appealing as it is biodegradable and FDA approved for use as a drug-delivery device. 18 Another option for local perivascular delivery in animal models is Pluronic F127 gel, which has established utility in early proof-of-concept studies. 19 Unfortunately, previous attempts at local delivery of anti-inflammatory agents to vasculature beds have been limited by significant toxicity associated with the drugs themselves, which delay rather than accelerate healing.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury

Mottola

Chatterjee

et al. 2017

Journal of Vascular Surgery

View full text Add to dashboard Cite

Objective Lipid mediators derived from omega-3 polyunsaturated fatty acids such as Resolvin D1 (RvD1) accelerate the resolution of inflammation, and have potential as vascular therapeutics. The objective of this study was to evaluate local perivascular delivery of RvD1 as a means to attenuate neointimal hyperplasia in a rat model of arterial injury. Methods Smooth muscle cells were harvested from rat aortas to study the effects of RvD1 on rat arterial vascular smooth muscle cell (RASMC) responses in vitro, with focus on inflammation, proliferation, migration, cytoskeletal changes and cytotoxicity. The safety and efficacy of perivascular delivery of RvD1 via thin biodegradable 3-layered PLGA wraps or 25% Pluronic F127 gels were studied in a rat model of carotid angioplasty. A total of 200 ng RvD1 was loaded into each construct for perivascular delivery after injury. Morphometric and histologic analyses were performed 3 and 14 days after injury. Results RvD1 attenuated RASMC inflammatory pathways, proliferation, migration and mitogen-induced cytoskeletal changes in vitro, without evidence of cytotoxicity. RvD1-loaded wraps reduced neointimal formation after carotid angioplasty by 59% versus no-wrap controls (P = .001) and by 45% versus vehicle-wrap controls (P = .002). RvD1-loaded pluronic gels similarly reduced neointimal formation by 49% versus no-gel controls (P = .02) and by 52% versus vehicle-gel controls (P = .02). No group was associated with infection, thrombosis or negative vessel remodeling. Wraps were found to be easier to apply than gel constructs. Ki67 proliferation index was significantly lower in RvD1-loaded wrap treated arteries compared to both no-wrap and vehicle-wrap controls at both 3 and 14 days post-injury (65% versus no-wrap group and 70% versus vehicle-wrap group at day 3, 49% versus both control groups at day 14, P < .05). Similarly, oxidative stress (30% and 29%, P < .05). and NF-kB activation (42% and 45%, p<.05) were significantly lower in the RvD1-loaded wrap group compared to both no-wrap and vehicle-wrap controls at three days post-injury Conclusions Local perivascular delivery of RvD1 attenuates formation of neointimal hyperplasia without associated toxicity in a rat model of carotid angioplasty. This effect is likely due to attenuation of inflammatory pathways as well as decreased arterial smooth muscle cell proliferation and migration.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury

Mottola

Chatterjee

et al. 2017

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…PLGA is a biodegradable synthetic polymer, which showed numerous advantages in tissue engineering applications [96]. The lack of bioactivity is the major drawback associated with PLGA [97]. The addition of bioactive glass can significantly improve the biological properties of PLGA-based scaffolds [98].…”

Section: Synthetic Polymer-based Biomaterialsmentioning

confidence: 99%

Advancement of Nanobiomaterials to Deliver Natural Compounds for Tissue Engineering Applications

Kumar

Abrahamse

2020

IJMS

View full text Add to dashboard Cite

Recent advancement in nanotechnology has provided a wide range of benefits in the biological sciences, especially in the field of tissue engineering and wound healing. Nanotechnology provides an easy process for designing nanocarrier-based biomaterials for the purpose and specific needs of tissue engineering applications. Naturally available medicinal compounds have unique clinical benefits, which can be incorporated into nanobiomaterials and enhance their applications in tissue engineering. The choice of using natural compounds in tissue engineering improves treatment modalities and can deal with side effects associated with synthetic drugs. In this review article, we focus on advances in the use of nanobiomaterials to deliver naturally available medicinal compounds for tissue engineering application, including the types of biomaterials, the potential role of nanocarriers, and the various effects of naturally available medicinal compounds incorporated scaffolds in tissue engineering.

show abstract

“…Among them, the most widely used polymer is poly( dl ‐lactide‐co‐glycolide) (PLGA). Many pharmaceutical substances have already been encapsulated in PLGA‐based delivery systems . The main advantage of PLGA particles as drug delivery systems is the ability to control the particle size, surface properties and rate of drug release from the polymer matrix, which allows to gain the site‐specific action of the drug at the optimal dosing regimen .…”

Section: Introductionmentioning

confidence: 99%

Development of novel PLGA nanoparticles with co‐encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells

et al. 2018

View full text Add to dashboard Cite

Co-encapsulation of abiraterone acetate (AbrA) and docetaxel (Dtx) in polymeric nanoparticles as novel prototypes for prostate cancer treatment combining hormonal and chemotherapy was designed. Nanoparticles (NPs) composed of poly(DL-lactide-co-glycolide) (PLGA) were prepared by singleemulsion solvent evaporation technique and characterized in terms of morphology with atomic force microscopy and transmission electron microscopy. HPLC method for simultaneous determination of AbrA and Dtx encapsulation efficacy was developed. Also differential scanning calorimetry and Fouriertransform infrared spectroscopy were provided. To study the effectiveness of cellular internalization and distribution of NPs with AbrA and Dtx co-encapsulation (NP-AbrA/Dtx), a fluorescence microscopy was utilized. NPs prepared had size 256.3 AE9.4 nm and zeta potential −18.4 AE1.4 mV. Encapsulation efficacy for AbrA was 68.7% and for Dtx was 74.3%. NPs were able to control the AbrA and Dtx release within 24 h. The mathematical model of drug release was performed. The results obtained from confocal microscopy showed the effective accumulation of the NP-AbrA/Dtx in the cytoplasm of cells. Synthesized NPs possessed satisfactory parameters and a biphasic release profile, proceeding by the Fick diffusion mechanism, which provide prolonged release of the drugs and maintenance of their concentration. It was shown that NPs loaded with AbrA and Dtx exhibited a high cytotoxic activity on the LNCaP cell line, similar to the combination of free drugs of AbrA and Dtx, but in contrast to the combination of substances, had a synergistic mechanism of action. Our findings support the potential use of developed NPs in further in vivo studies.How to cite this article: Sokol MB, Nikolskaya ED, Yabbarov NG, Zenin VA, Faustova MR, Belov AV, Zhunina OA, Mollaev MD, Zabolotsky AI, Tereshchenko OG, Severin ES. 2019. Development of novel PLGA nanoparticles with co-encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells. J Biomed Mater Res Part B 2019:107B:1150-1158.

show abstract

Poly(Lactic-Co-Glycolic Acid) Based Drug Delivery Devices For Tissue Engineering And Regenerative Medicine

Abstract: SUMMARYPoly (D,L-lactide-co-glycolide) ANKEM Derg 2012;26(2):86-98

Cited by 32 publications

References 78 publications

Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury

Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury

Advancement of Nanobiomaterials to Deliver Natural Compounds for Tissue Engineering Applications

Development of novel PLGA nanoparticles with co‐encapsulation of docetaxel and abiraterone acetate for a highly efficient delivery into tumor cells

Contact Info

Product

Resources

About